Selvigaltin (GB1211), an orally obtainable small molecule galectin-three inhibitor developed being a treatment for liver fibrosis and cirrhosis, was evaluated to assess the influence of hepatic impairment on its pharmacokinetics and safety to address regulatory necessities. Members had been also excluded if they'd clinically important abnormalities in electrocardiogram (ECG) results https://robertu010kwg3.blogaritma.com/profile